XNCR
Xencor·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XNCR
Xencor, Inc.
A biotech company that develops monoclonal antibodies for cancer and autoimmune diseases
465 North Halstead Street, Suite 200, Pasadena, CA 91107
--
Xencor, Inc., was founded in California in August 1997 and reorganized in Delaware in September 2004. The Company is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies and cytokine therapies for the treatment of cancer and autoimmune disease patients with unmet medical needs. The company utilizes protein engineering capabilities to increase understanding of protein structures and interactions and to design new technologies and XmAb drug candidates with improved properties.
Company Financials
EPS
XNCR has released its 2025 Q3 earnings. EPS was reported at -0.08, versus the expected -0.7, beating expectations. The chart below visualizes how XNCR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XNCR has released its 2025 Q3 earnings report, with revenue of 21.00M, reflecting a YoY change of 18.00%, and net profit of -6.03M, showing a YoY change of 87.30%. The Sankey diagram below clearly presents XNCR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
